Combination Drug-Therapy for Patients With Untreated Obstructive Sleep Apnea
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
Obstructive sleep apnea (OSA) is common and associated with many adverse health consequences,
but many patients are unable to tolerate standard therapies such as continuous positive
airway pressure (CPAP) and thus remain untreated. Single-drug therapies have shown promising
results in treating sleep apnea, but on average patients have only experienced partial
relief. Multi-drug therapy may offer a more effective treatment approach. The goal of this
study is to test the effect of combination therapy with three FDA-approved drugs (Diamox
[acetazolamide], Lunesta [eszopiclone] +/- Effexor [venlafaxine]) on OSA severity and
physiology.